Analysts Offer Predictions for Prothena FY2025 Earnings

Prothena Co. plc (NASDAQ:PRTA) – Stock analysts at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for shares of Prothena in a research report issued on Monday, March 24th. Chardan Capital analyst R. Li forecasts that the biotechnology company will post earnings of ($3.25) per share for the year. Chardan Capital currently has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Prothena’s current full-year earnings is ($4.04) per share.

PRTA has been the topic of several other research reports. Piper Sandler lifted their target price on shares of Prothena from $94.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Royal Bank of Canada lowered their price objective on Prothena from $24.00 to $20.00 and set a “sector perform” rating on the stock in a report on Friday, February 21st. HC Wainwright reissued a “buy” rating and set a $48.00 target price on shares of Prothena in a report on Friday, February 21st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Prothena in a research note on Friday, February 21st. Finally, Bank of America reduced their price objective on Prothena from $26.00 to $22.00 and set a “neutral” rating for the company in a research note on Thursday, December 19th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $55.00.

Prothena Stock Performance

Prothena stock opened at $13.01 on Thursday. The stock has a market capitalization of $700.29 million, a P/E ratio of -5.66 and a beta of -0.02. The company’s fifty day moving average price is $14.33 and its 200 day moving average price is $15.66. Prothena has a 1 year low of $11.70 and a 1 year high of $26.36.

Prothena (NASDAQ:PRTA) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.06). The business had revenue of $2.12 million during the quarter, compared to analysts’ expectations of $7.53 million. Prothena had a negative net margin of 90.50% and a negative return on equity of 22.67%.

Institutional Investors Weigh In On Prothena

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Intech Investment Management LLC purchased a new stake in Prothena in the 3rd quarter valued at $210,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Prothena during the 3rd quarter valued at about $432,000. The Manufacturers Life Insurance Company grew its holdings in shares of Prothena by 3.8% in the third quarter. The Manufacturers Life Insurance Company now owns 86,071 shares of the biotechnology company’s stock valued at $1,440,000 after purchasing an additional 3,163 shares during the period. BNP Paribas Financial Markets increased its position in Prothena by 44.6% during the third quarter. BNP Paribas Financial Markets now owns 55,842 shares of the biotechnology company’s stock worth $934,000 after purchasing an additional 17,230 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Prothena by 1,122.9% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 526,748 shares of the biotechnology company’s stock worth $8,812,000 after purchasing an additional 483,673 shares during the period. Institutional investors and hedge funds own 97.08% of the company’s stock.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson’s disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer’s disease.